Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Free Cash Flow (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Free Cash Flow for 16 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 166.11% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2025, up 287.13% year-over-year, with the annual reading at $4.4 million for FY2025, 287.13% up from the prior year.
  • Free Cash Flow for Q4 2025 was $4.0 million at Anika Therapeutics, down from $5.0 million in the prior quarter.
  • The five-year high for Free Cash Flow was $10.1 million in Q3 2024, with the low at -$7.0 million in Q2 2023.
  • Average Free Cash Flow over 5 years is $605550.0, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 984.47% in 2021, then surged 1232.64% in 2023.
  • Over 5 years, Free Cash Flow stood at $4.7 million in 2021, then tumbled by 89.72% to $481000.0 in 2022, then soared by 1232.64% to $6.4 million in 2023, then plummeted by 194.13% to -$6.0 million in 2024, then soared by 166.11% to $4.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $4.0 million, $5.0 million, and -$1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.